A Phase 2 interventional study of Vamorolone 0.25 mg/day/day and Vamorolone 0.75 mg/day/day in Duchenne Muscular Dystrophy, sponsored by ReveraGen BioPharma, Inc.. Completed at 12 sites in 6 countries. Open to male participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2021-05-20.
Sponsored by ReveraGen BioPharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 62nd largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2017, is one of 57 in phase 2, and was the 113th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 7 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 90 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 171 interventional studies, 75 across the 55 observational. Of the 160 that completed or were terminated, 78 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 232 have an industry lead sponsor. The 10 most frequent:
ReveraGen BioPharma, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
ReveraGen BioPharma, Inc. has 5 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
20 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT03368742Solid Biosciences Inc.Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | 2026-11-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This long-term extension study is an open-label, multiple-dose study to evaluate the long-term safety, tolerability, efficacy and PD of vamorolone administered once daily by liquid oral suspension over a Treatment Period of 24 months to young boys with DMD who participated in the VBP15-002 Phase IIa and VBP15-003 Phase IIa extension core studies.
This study will evaluate if it is safe to use a new medication called vamorolone for more than two weeks in children with DMD, if boys with DMD who take the study medication have improved muscle function compared to boys with DMD in other studies who did not take any type of steroid, and to see if boys with DMD who take the study medication gain less weight compared to boys with DMD in a prior study who took another type of steroid called prednisone. Enrolled participants will take the study medication for 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Subjects may be re-evaluated if ineligible due to a transient condition which would prevent the subject from participating.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Drug: Vamorolone 0.25 mg/day/day
Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Drug: Vamorolone 0.75 mg/day/day
Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Drug: Vamorolone 2.0 mg/day/day
Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Drug: Vamorolone 6.0 mg/day/day
Drug page: Vamorolone
Oral administration of 0.25 mg/kg/day daily for 24 months.
Also known as: VBP15
Drug page: Vamorolone
Oral administration of 0.75 mg/kg/day daily for 24 months.
Also known as: VBP15
Drug page: Vamorolone
Oral administration of 2.0 mg/kg/day daily for 24 months.
Also known as: VBP15
Drug page: Vamorolone
Oral administration of 6.0 mg/kg/day daily for 24 months.
Also known as: VBP15
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.03
To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- month Treatment Period, in boys ages 4-7 years with DMD; Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination);
Time frame: 24 months
Total Number of Adverse Events as Assessed by CTCAE Version 4.03
To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24-month Treatment Period, in boys ages 4-7 years with DMD. Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination).
Time frame: 24 Months
| Milestone | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Started | 11 | 12 | 12 | 11 |
| Completed | 10 | 11 | 11 | 9 |
| Not completed | 1 | 1 | 1 | 2 |
To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- month Treatment Period, in boys ages 4-7 years with DMD; Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination);
| Participants | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Dose Level Group 5 |
|---|---|---|---|---|---|
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.03 | 4 | 14 | 29 | 1 | 39 |
To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24-month Treatment Period, in boys ages 4-7 years with DMD. Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination).
| Events | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Dose Level Group 5 |
|---|---|---|---|---|---|
| Total Number of AEs | 15 | 34 | 203 | 5 | 302 |
| Total Number of TEAEs | 14 | 34 | 202 | 5 | 300 |
Collected over Adverse events, including Serious Adverse Events (SAEs), and concomitant medications will be assessed at each study visit and recorded throughout the 24 months treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level Group 1 | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Dose Level Group 2 | 0/23 (0%) | 1/23 (4.3%) | 14/23 (60.9%) |
| Dose Level Group 3 | 0/38 (0%) | 0/38 (0%) | 29/38 (76.3%) |
| Dose Level Group 4 | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Dose Level Group 5 | 0/41 (0%) | 1/41 (2.4%) | 39/41 (95.1%) |
| Event | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Dose Level Group 5 |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/11 | 1/23 | 0/38 | 0/3 | 0/41 |
| MyoglobinuriaRenal and urinary disorders | 0/11 | 0/23 | 0/38 | 0/3 | 1/41 |
| Event | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Dose Level Group 5 |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/11 | 1/23 | 1/38 | 1/3 | 3/41 |
| VomitingGastrointestinal disorders | 1/11 | 0/23 | 5/38 | 1/3 | 7/41 |
| UrticariaSkin and subcutaneous tissue disorders | 0/11 | 0/23 | 0/38 | 1/3 | 1/41 |
| Lipids AbnormalInvestigations | 0/11 | 0/23 | 0/38 | 1/3 | 0/41 |
| Gastroenteritis viralInfections and infestations | 0/11 | 0/23 | 0/38 | 1/3 | 2/41 |
| NasopharyngitisInfections and infestations | 0/11 | 1/23 | 7/38 | 0/3 | 12/41 |
| Weight increasedInvestigations | 0/11 | 0/23 | 2/38 | 0/3 | 10/41 |
| PyrexiaGeneral disorders | 0/11 | 0/23 | 9/38 | 0/3 | 8/41 |
| ConstipationGastrointestinal disorders | 0/11 | 0/23 | 3/38 | 0/3 | 8/41 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/11 | 1/23 | 7/38 | 0/3 | 8/41 |
Subjects entered this study in one of 4 dose level groups, but were allowed to escalate/de-escalate during the course of the study.
| Age, Continuous(years) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Mean | 5.87 ± 1.135 | 5.11 ± 0.805 | 5.13 ± .964 | 5.27 ± 0.856 | 5.33 ± 0.965 |
| Sex: Female, Male(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 11 | 12 | 12 | 11 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 3 | 4 |
| Not Hispanic or Latino | 11 | 11 | 12 | 8 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 |
| White | 10 | 10 | 12 | 11 | 43 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Canada | 3 | 0 | 2 | 2 | 7 |
| Sweden | 0 | 4 | 0 | 0 | 4 |
| United States | 8 | 3 | 2 | 5 | 18 |
| United Kingdom | 0 | 0 | 4 | 2 | 6 |
| Israel | 0 | 3 | 2 | 0 | 5 |
| Australia | 0 | 2 | 2 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Apr 2020, 38 months.
Results were first posted in May 2021, 1 year after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 38 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vamorolone
Muscular Dystrophy, Duchenne →
ReveraGen BioPharma, Inc.